Premium
Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis. Reversal with VP‐16 and indomethacin
Author(s) -
Brown R. E.,
Bowman W. P.,
D'Cruzmd C. A.,
Pick T. E.,
Champion J. E.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19871115)60:10<2388::aid-cncr2820601007>3.0.co;2-a
Subject(s) - medicine , hyperlipidemia , hemophagocytic lymphohistiocytosis , histiocyte , prostaglandin , gastroenterology , endocrinology , pathology , disease , diabetes mellitus
Clinicopathologic and histopathologic evidence of both endoperoxidation with hyperprostaglandinemia and hyperlipidemia in a 5‐week‐old infant with a hemophagocytic syndrome is reported. Institution of histiocytolytic (VP‐16) and cyclo‐oxygenase inhibitor (indomethacin) therapies returned the prostaglandin levels and lipid profile to a nearly normal state coincidental with clinical recovery. It appears that by reducing the cell mass of histiocytes and controlling the over‐production of prostaglandins, some types of hemophagocytic syndrome can be reversed.